Evidence map›Paper›PMID 36358850›Full record

ArticleCancers2022

Feasibility and Safety of Single-Probe Cryoablation with Liquid Nitrogen: An Initial Experience in 24 Various Tumor Lesions.

Tarek Kammoun, Elodie Prévot, Chris Serrand, Romain Perolat, Hélène de Forges, Nadine Houédé, Jean-Paul Beregi, Julien Frandon

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. [Clinical strategies and indication expansion of interventional ultrasonography ablative therapy for hepatic tumors].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Tarek KammounDepartment of Medical Imaging, Nimes University Hospital, University of Montpellier, Medical Imaging Group Nimes, 30029 Nimes, France.
Elodie PrévotDepartment of Medical Imaging, Nimes University Hospital, University of Montpellier, Medical Imaging Group Nimes, 30029 Nimes, France.
Chris SerrandDepartment of Biostatistics, Clinical Epidemiology, Public Health, and Innovation in Methodology (BESPIM), CHU Nimes, 30029 Nimes, France.
Romain PerolatDepartment of Medical Imaging, Nimes University Hospital, University of Montpellier, Medical Imaging Group Nimes, 30029 Nimes, France.
Hélène de ForgesDepartment of Medical Imaging, Nimes University Hospital, University of Montpellier, Medical Imaging Group Nimes, 30029 Nimes, France.
Nadine HouédéGard Cancer Institute, Nimes University Hospital, University of Montpellier, 30029 Nimes, France.
Jean-Paul BeregiDepartment of Medical Imaging, Nimes University Hospital, University of Montpellier, Medical Imaging Group Nimes, 30029 Nimes, France.
Julien FrandonDepartment of Medical Imaging, Nimes University Hospital, University of Montpellier, Medical Imaging Group Nimes, 30029 Nimes, France.ORCID 0000-0001-7816-8178
Université de Montpellier · FRCentre Hospitalier Universitaire de Montpellier · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPercutaneous cryoablation with liquid nitrogen is a new technique being used in the treatment of some malignant tumors. Our objective was to assess its feasibility in the ablation of tumor lesions of various sizes and locations.

methodsThis retrospective, monocentric study included all consecutive patients who underwent percutaneous cryoablation with liquid nitrogen between December 2019 and March 2021. Cryoablation was performed using 10G or 13G cryoprobes. The ablation volume was measured on post-treatment CT or MRI.

results22 patients (24 lesions) were included, 16 of whom were men (73%), while median age was 66 years. The lesions were located in the bone (42%), kidney (29%), soft tissue (17%), lung (8%), or liver (4%). It was feasible in all tumor locations and produced median ablation zones 25 mm in width and 35 mm in length, with a 23 min median freezing time. Freezing duration was correlated with the ice volume ( DISCUSSION: We showed that this technique was safe and feasible in all organs tested. The freezing duration was correlated with the ice ball size, but not with the ablation zone.

Indexed as

cryoablationliquid nitrogenpercutaneous ablationsingle probe

Identifiers

PMID36358850
PMCPMC9655210
OpenAlexW4308207140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.